Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 988 of 6351
-
New pill targets genetic weakness in Hard-to-Treat blood cancers
Disease control OngoingThis is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Artificial pancreas put to the test in teens over two years
Disease control CompletedThis study designed to assess changes in control of Type 1 Diabetes in pubertal adolescents over a two year period. There are two arms/substudies, the first being a longitudinal randomized controlled trial and the second an observational study.
Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a simple antibiotic taper stop c. diff relapse?
Prevention CompletedThe first line therapy for an initial episode of CDI (Clostridium difficile infection) is 10-14 days of oral vancomycin which is now recommended over metronidazole in the 2018 guidelines from the Association of Medical Microbiologists and Infectious Diseases of Canada (AMMI). Alt…
Phase 3 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
Can a bedtime snack tame overnight blood sugar swings in kids with diabetes?
Disease control CompletedThis study compared four types of bedtime snacks in children and adolescents with type 1 diabetes treated with multiple daily insulin injections. The aim was to determine whether bedtime snack nutrient composition affects overnight glucose levels. Participants received four diff…
Sponsor: Didem Güneş Kaya • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
One-Time radiation during breast surgery could cut treatment time
Disease control Recruiting nowA Single-center, open, prospective study,for analyzing the local recurrence rate, the incidence of incision complications and the aesthetic effect of intraoperative radiotherapy in early breast cancer patients after breast-conserving surgery.
Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 26, 2026 17:00 UTC
-
Immunotherapy boosts chemo in aggressive breast cancer trial
Disease control Stopped earlyPrior to Amendment #7: The hypothesis of this study is that the combination of cabiralizumab and nivolumab with neoadjuvant chemotherapy will decrease tumor associated macrophages (TAMs) and increase tumor infiltrating lymphocytes (TIL) compared to neoadjuvant chemotherapy plus n…
Phase 1/2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Simple blood test could spot returning throat cancer sooner
Diagnosis OngoingIn this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
Sponsor: Dana-Farber Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Can a lung drug stop COVID scarring?
Disease control CompletedThis is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of lung disease in patients who have been diagnosed with …
Phase 4 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Early use of powerful CF drugs may boost growth in young children
Disease control Recruiting nowThis is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).
Sponsor: Sonya Heltshe • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Lung cancer drug shows promise against brain metastases
Disease control CompletedThis will be a Phase II, open-label, single-arm, multicenter study of the efficacy and safety of osimertinib (80 mg orally once daily) in patients with LM associated with EGFRm+ NSCLC.
Phase 2 • Sponsor: Sehhoon Park • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Polio virus turned against skin cancer in new trial
Disease control CompletedA Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
Phase 2 • Sponsor: Istari Oncology, Inc. • Aim: Disease control
Last updated Jun 26, 2026 19:20 UTC
-
PET scans reveal how inflammation drives Alzheimer's variants
Knowledge-focused Recruiting nowThe purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheime…
Phase 2 • Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
New device could offer stroke prevention without blood thinners for heart patients
Disease control OngoingThe purpose of the study is to assess the safety and performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in LAA (Left Atrial Appendage) closure for patients with non-valvular atrial fibrillation (NVAF) and high bleeding risk.
Sponsor: Eclipse Medical Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a smart lung monitor outsmart asthma symptoms?
Disease control Stopped earlySelf-management strategies for asthma, including patients engagement and adherence to personalised action plans with advice on recognizing and responding to deterioration in control with effective treatments can improve asthma outcomes and possibly reduce the risk of future exace…
Sponsor: Restech Srl • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug combo offers hope for hard-to-treat lymphoma patients
Disease control Recruiting nowThis is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of Anti-PD-1 antibody(Sintilimab) plus HDAC inhibitor(Chidamide) in patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for rare heart disease: drug shows promise in japanese trial
Disease control CompletedThis prospective study is designed to evaluate the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a background of stable…
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
ALS drug trial halted: oral Edaravone's promise unfulfilled
Disease control Stopped earlyTo evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to Week 48:
Phase 3 • Sponsor: Shionogi • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can breathing exercises supercharge stroke recovery?
Disease control CompletedThe goal of this clinical trial is to test the hypothesis that combined Respiratory Muscle Training and a Stroke Wellness Program is more effective than a Stroke Wellness Program alone for stroke survivors with and without a smoking exposure history. Participants will participan…
Sponsor: University of Florida • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Radiation boosts standard therapy in advanced breast cancer trial
Disease control Recruiting nowWomen with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also …
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the kappa light chain antibody on c…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC